ArticleFrontiers in endocrinology2025
The biological and immunological significance of the estrogen-related gene IER3 in diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research on the role and mechanisms of Cystatin 6 in disease pathosis and development.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes Mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia, primarily arising from insufficient insulin secretion or the development of insulin resistance. Estrogen plays a significant role in regulating the occurrence and progression of DM. This study aims to investigate the role of estrogen-related genes in diabetes, focusing on identifying potential biomarkers and therapeutic targets for the disease. Methods: We initially obtained gene expression datasets related to type 2 diabetes mellitus (T2DM) from the GEO database. A systematic and coherent series of methodologies was then implemented in a structured manner. First, Principal Component Analysis (PCA) was employed for preliminary data exploration and dimensionality reduction. Next, we identified Differentially Expressed Genes (DEGs). Subsequently, we conducted Weighted Gene Co-expression Network Analysis (WGCNA) to uncover gene modules associated with DM. This was followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to explore the biological functions and pathways associated with the identified genes. To enhance the precision of biomarker identification, we applied three distinct machine learning algorithms, including Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine-Recursive Feature Elimination (SVM-RFE), and Random Forest (RF), for further refined selection. This comprehensive approach ultimately identified the estrogen-related gene IER3 as a promising biomarker for DM. Furthermore, correlation analyses focusing on immune cell infiltration were conducted to clarify the immunological role of IER3 in DM. Results: Our findings revealed a significant downregulation of IER3 in DM patients, accompanied by an AUC value of 0.723 in the diagnostic curve ROC, indicating its considerable diagnostic and prognostic potential for DM. Furthermore, the expression levels of IER3 exhibited a strong correlation with variations in the proportions of diverse immune cell types, suggesting that it may play a pivotal role in the immunoregulatory mechanisms underlying DM. Conclusion: In conclusion, our findings reveal that the estrogen-related gene IER3 is significantly downregulated in patients with DM, highlighting its potential as a diagnostic and prognostic marker for the disease. Therefore, IER3 may serve as a promising biomarker and therapeutic target for DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.